Paul E Goss
Overview
Explore the profile of Paul E Goss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
5902
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapman J, Bayani J, SenGupta S, Bartlett J, Piper T, Quintayo M, et al.
J Clin Oncol
. 2024 Jun;
42(24):2887-2898.
PMID: 38824432
Purpose: ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity...
2.
Li Y, Zheng X, Tu D, Ingle J, Goss P, Parulekar W, et al.
Breast Cancer Res Treat
. 2021 Nov;
191(3):523-533.
PMID: 34825307
Purpose: Women with hormone receptor positive breast cancer may receive 5 years of treatment with aromatase inhibitors but the magnitude of benefit was relatively small. Our goal was to develop...
3.
Jindal S, Pennock N, Sun D, Horton W, Ozaki M, Narasimhan J, et al.
Nat Commun
. 2021 Nov;
12(1):6341.
PMID: 34732713
Young women's breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5-10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared...
4.
Xu J, Keenan T, Overmoyer B, Tung N, Gelman R, Habin K, et al.
Breast Cancer Res Treat
. 2021 Aug;
189(3):641-651.
PMID: 34417675
Purpose: We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations....
5.
Cairns J, Kalari K, Ingle J, Shepherd L, Ellis M, Goss P, et al.
Clin Pharmacol Ther
. 2021 May;
110(4):1038-1049.
PMID: 34048027
Aromatase inhibitors (AIs) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of...
6.
Duarte C, Salazar A, Strasser-Weippl K, de Vries E, Wiesner C, Arango-Gutierrez A, et al.
Breast Cancer Res Treat
. 2021 Feb;
186(1):15-24.
PMID: 33611666
Aim: To provide a comprehensive overview of breast cancer in Colombia. Methods: Data on breast cancer in Colombia are scarce. We present incidence data from population-based cancer registries that represent...
7.
Soto-Perez-de-Celis E, Chavarri-Guerra Y, Ramos-Lopez W, Alcalde-Castro J, Covarrubias-Gomez A, Navarro-Lara A, et al.
Oncologist
. 2020 Nov;
26(2):157-164.
PMID: 33210345
Background: The early integration of supportive care in oncology improves patient-centered outcomes. However, data are lacking regarding how to achieve this in resource-limited settings. We studied whether patient navigation increased...
8.
Cairns J, Ingle J, Dudenkov T, Kalari K, Carlson E, Na J, et al.
JCI Insight
. 2020 Jul;
5(16).
PMID: 32701512
Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase...
9.
Ingle J, Kalari K, Barman P, Shepherd L, Ellis M, Goss P, et al.
Pharmacogenet Genomics
. 2020 Jul;
31(1):1-9.
PMID: 32649577
Objectives: Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/ml and 0.5 pg/ml, respectively, after 6 months of adjuvant...
10.
Richardson H, Ho V, Pasquet R, Singh R, Goetz M, Tu D, et al.
Menopause
. 2020 May;
27(6):693-700.
PMID: 32433262
Objective: The aim of the study was to quantify baseline estradiol (E2) and estrone (E1) concentrations according to selected patient characteristics in a substudy nested within the MAP.3 chemoprevention trial....